Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think...
Transcript of Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think...
![Page 1: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/1.jpg)
Recombinant Activated Protein C in ScotlandSICSAG Trainee Sprint Audit
How we use itWhat we think about it(not going to get into should we use it!)
Alex Puxty SpR
![Page 2: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/2.jpg)
![Page 3: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/3.jpg)
OUTLINE
•Background▫The PROWESS trial▫Controversies
•The audit-▫Objectives▫Methods▫Results▫Conclusions
![Page 4: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/4.jpg)
BACKGROUND
• PROWESS study published in 2001
• FDA approval in early 2002
• European licence six months later
• Adopted into both Surviving sepsis and NICE guidelines (2004)
![Page 5: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/5.jpg)
PROWESS
•Randomized, double blind trial
•164 centres (none in UK)
•1690 patients
•Severe sepsis of less than 24hrs duration
![Page 6: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/6.jpg)
PROWESS-HEADLINE RESULTS
•19.4% RRR of death (6.1% ARR); p=0.005
•Trend towards more bleeding (3.5% Vs 2%; p=0.06)
![Page 7: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/7.jpg)
PROWESS-CONTROVERSIES
![Page 8: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/8.jpg)
GUIDELINES•NICE 2004-
The intervention is a cost-effective option for use in severe sepsis whose risk of death was increased due to multiple organ failure
•SURVIVING SEPSIS 2004rhAPC is recommended in patients at highrisk of death (APACHE II ≥ 25, sepsis-
inducedmultiple organ failure, septic shock, orsepsis-induced acute respiratory distresssyndrome [ARDS]) and with no absolutecontraindication related to bleeding risk orrelative contraindication that outweighsthe potential benefit of rhAPC
![Page 9: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/9.jpg)
GUIDELINES
•SURVIVING SEPSIS 2008
Consider rhAPC in adult patients with sepsis induced organ dysfunction with clinical assessment of high risk of death (typically APACHE II ≥25 or multiple organ failure) if there are no contra-indications
![Page 10: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/10.jpg)
RESOLVE AND ADDRESS
•RESOLVE Not a mortality study Stopped early as little chance of reaching
efficacy endpoint
•ADDRESS Stopped after 2nd interim analysis <5% chance of reaching endpoint of significant
mortality reduction
![Page 11: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/11.jpg)
COCHRANE 2008
This review found no evidence suggesting that APC should be used for treating patients with severe sepsis or septic shock. Additionally, APC seems to be associated with a higher risk of bleeding. Unless additional RCTs provide evidence of a treatment effect, policy-makers, clinicians and academics should not promote the use of APC.
![Page 12: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/12.jpg)
The Audit ItselfWhat is the trainee Sprint audit again?
![Page 13: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/13.jpg)
SICSAG TRAINEE SPRINT AUDIT•3RD audit carried out
•Previously audit of thromboprophylaxis
•R+R audit
![Page 14: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/14.jpg)
![Page 15: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/15.jpg)
![Page 16: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/16.jpg)
GETTING STARTED• Proposal to SICSAG committee
• Three regional coordinators
• Further recruitment to total 24 data collectors
• Protocol written
• Database formed
• Pilot
![Page 17: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/17.jpg)
OBJECTIVES
•To determine the pattern of usage of rAPC in Scottish ICU’s
•Compare this to published guidelines
•Determine consultants attitudes towards rAPC
![Page 18: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/18.jpg)
![Page 19: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/19.jpg)
METHODS
•Two parts:
2 week data collection
Questionnaire to all consultants with ICU sessions
![Page 20: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/20.jpg)
METHODS
•Two parts:
2 week data collection
Questionnaire to all consultants with ICU sessions
![Page 21: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/21.jpg)
DATA COLLECTION
•All patients admitted with severe sepsis
•2 weeks beginning second week of January 2008
•Followed up for 72hrs split into 4 time periods
![Page 22: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/22.jpg)
DATA COLLECTION
•Demographics•Source sepsis•Organ failures•APACHE II score•Contra-indications•Reasons recorded for not prescribing (if
needed)•Inotropes (converted to mcg/kg/min)•INR
![Page 23: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/23.jpg)
DATA COLLECTION
SICSAG provided:
Unit and hospital LOS
Predicted mortality
Mortality
![Page 24: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/24.jpg)
RESULTS
•97 patients
•49 (51.5%) male
•Mean age 59.8yrs
•Median APACHE II -25
![Page 25: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/25.jpg)
RESULTS
•Overall 66 of 97 had outcome data
•In these, mean predicted mortality was 45.9%
•Actual mortality was 36.3% (SMR 0.79)
![Page 26: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/26.jpg)
APACHE II SCORES RECORDED
![Page 27: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/27.jpg)
DIVIDING THE PATIENTS
•Stratified-split into 3 categories
•Excluded all with contra-indications
•Split into NICE and SSC guidelines
![Page 28: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/28.jpg)
ORGAN FAILURE CRITERIA
![Page 29: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/29.jpg)
ORGAN FAILURE CRITERIA
![Page 30: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/30.jpg)
PERCENTAGE OF PRESCRIPTIONS “MISSED”-
ORGAN CRITERIA
![Page 31: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/31.jpg)
APACHE II CRITERIA
![Page 32: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/32.jpg)
APACHE II CRITERIA
![Page 33: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/33.jpg)
PERCENTAGE OF PRESCRIPTIONS “MISSED”-
APACHE II CRITERIA
![Page 34: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/34.jpg)
CONTRA-INDICATIONS
![Page 35: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/35.jpg)
WHO DID GET rAPC?
•Median APACHE II-33
•All on inotropes
•No age difference
•Median organ failures -4
![Page 36: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/36.jpg)
![Page 37: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/37.jpg)
![Page 38: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/38.jpg)
THOSE WHO GOT rAPC
![Page 39: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/39.jpg)
CONCLUSIONS OF DATA COLLECTION•No one got rAPC who did not qualify by
either criteria
•Contra-indications were common (33%)
•rAPC seemed to be used only in some of the sicker patients
![Page 40: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/40.jpg)
CONCLUSIONS OF DATA COLLECTIONUsing organ failure criteria:
• Between 61% and 79% “missed” prescription of rAPC
Using APACHE II criteria:
• Between 50% and 71% “missed” prescription of rAPC
![Page 41: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/41.jpg)
THE QUESTIONNAIREDONT WORRY, WE’RE MORE THAN HALF WAY!
![Page 42: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/42.jpg)
METHODS
•Direct contact!
•All consultants with daytime ICU sessions
•After data collection complete
•125/162 returns=77% response rate
![Page 43: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/43.jpg)
![Page 44: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/44.jpg)
![Page 45: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/45.jpg)
DO YOU BELIEVE THE EVIDENCE IN SUPPORT OF rAPC
![Page 46: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/46.jpg)
![Page 47: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/47.jpg)
Organ/System Failure Median Score
CVS 1
Respiratory 3
Renal 3
Metabolic 4
Haematological 5
![Page 48: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/48.jpg)
SCENARIO
You have a patient with chest sepsis with a reduced blood pressure and acute kidney injury. You use all standard therapies over the first day of treatment.The inotrope requirement reduces and the ventilation improves slightly. THEY STILL MEET CRITERIA FOR rAPC.
![Page 49: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/49.jpg)
CLINICAL SCENARIO-WOULD YOU PRESCRIBE?
![Page 50: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/50.jpg)
CONCLUSIONS FROM QUESTIONNAIRE•In no unit did all consultants say they did
not use rAPC
•Despite this, there remains significant concern regarding the current evidence
•Cardiovascular failure is generally felt to be the most important “system”
•Most consultants would use discretion in prescription
![Page 51: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/51.jpg)
RECOMMENDATIONS
•Be aware that more patients are qualifying for treatment than are currently being considered
•Record decisions in notes
•Ideally single guideline
![Page 52: Recombinant Activated Protein C in Scotland SICSAG Trainee Sprint Audit How we use it What we think about it (not going to get into should we use it!)](https://reader035.fdocuments.us/reader035/viewer/2022081519/56649f535503460f94c77305/html5/thumbnails/52.jpg)
ACKNOWLEDGEMENTS• SICSAG (in particular Angela Kellacher, Catriona Haddow,
Sarah Ramsay and Brian Cook) • Paul McConnell, Simon Crawley, Simon McAree
Lia Paton Jane Wilkinson Laura Robertson
Tim Geary Catriona Chalmers Ewan McMillan
Dave Griffiths Claire Tordoff Richard Appleton
Craig Beattie Kirankumar Sachane Andrew Goddard
Jonathan Antrobus Gordon Houston Andrew Clarkin
Fahmi Faraz Megan Dale Raj Najeurs
Euan McGregor Prit Anand Singh Myra McAdam
Bhushan Joshi John Glen